Exact peptide identities attached to retained registry observations carrying this condition label.
Official registry condition
Relapsed Multiple Myeloma peptide trials
2 selected ClinicalTrials.gov records carrying the official condition label Relapsed Multiple Myeloma. The label is copied from each retained registry version and does not imply that PeptideScanner has verified a diagnosis, treatment relationship, or study result.
2 selected records.
1 profiles.
2022–2025 in selected records.
Indication intelligence
Selected evidence landscape
Phase labels copied from the retained ClinicalTrials.gov versions.
Overall statuses at each retained observation, not necessarily current today.
Across the connected peptide profiles, PeptideScanner also carries 25 selected PubMed records and 6 selected Drugs@FDA applications. Those records are profile context only; PeptideScanner does not claim they concern Relapsed Multiple Myeloma unless their own cited source says so.
Collection change ledger
Recently changed records on this condition hub
These events come only from the exact registry records shown on this page. The condition label does not establish a diagnosis, treatment relationship, or scientific agreement.
ClinicalTrials.gov record NCT01080391
PeptideScanner retained ClinicalTrials.gov record NCT01080391 at 2026-11-16T17:39:29.005Z. Its registry update date was 2022-09-21, and PeptideScanner's reviewed identity mapping was carfilzomib.
- PeptideScanner change date
- November 16, 2026
- Cited source date
- September 21, 2022
- Evidence lane
- Clinical trials
ClinicalTrials.gov record NCT03158688
PeptideScanner retained ClinicalTrials.gov record NCT03158688 at 2026-11-16T17:39:29.005Z. Its registry update date was 2025-05-09, and PeptideScanner's reviewed identity mapping was carfilzomib.
- PeptideScanner change date
- November 16, 2026
- Cited source date
- May 9, 2025
- Evidence lane
- Clinical trials
Attributed registry records
Selected records
Carfilzomib · 2025-05-09
ClinicalTrials.gov record NCT03158688
Completed at the retained observation.
Open attributed record →Carfilzomib · 2022-09-21
ClinicalTrials.gov record NCT01080391
Completed at the retained observation.
Open attributed record →